Bruker Co. (NASDAQ:BRKR) has received a consensus recommendation of “Hold” from the seventeen ratings firms that are currently covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, ten have assigned a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $31.83.
Several analysts have issued reports on BRKR shares. BTIG Research started coverage on Bruker in a research note on Friday, January 5th. They issued a “buy” rating and a $42.00 target price for the company. Zacks Investment Research raised Bruker from a “hold” rating to a “buy” rating and set a $39.00 target price for the company in a research note on Thursday, January 4th. BidaskClub lowered Bruker from a “strong-buy” rating to a “buy” rating in a research note on Thursday, January 11th. Morgan Stanley reaffirmed an “equal weight” rating and issued a $35.00 target price on shares of Bruker in a research note on Thursday, December 14th. Finally, Cowen reaffirmed a “hold” rating and issued a $29.00 target price on shares of Bruker in a research note on Friday, November 3rd.
Hedge funds have recently made changes to their positions in the business. Koch Industries Inc. lifted its position in Bruker by 2,573.5% in the second quarter. Koch Industries Inc. now owns 334,774 shares of the medical research company’s stock valued at $324,000 after purchasing an additional 322,252 shares during the last quarter. Cubist Systematic Strategies LLC lifted its position in Bruker by 186.3% in the second quarter. Cubist Systematic Strategies LLC now owns 16,478 shares of the medical research company’s stock valued at $475,000 after purchasing an additional 10,723 shares during the last quarter. Teachers Advisors LLC lifted its position in Bruker by 65.8% in the second quarter. Teachers Advisors LLC now owns 245,720 shares of the medical research company’s stock valued at $7,087,000 after purchasing an additional 97,491 shares during the last quarter. Verition Fund Management LLC lifted its position in Bruker by 95.6% in the second quarter. Verition Fund Management LLC now owns 26,891 shares of the medical research company’s stock valued at $776,000 after purchasing an additional 13,140 shares during the last quarter. Finally, Stifel Financial Corp bought a new stake in Bruker in the second quarter valued at approximately $575,000. Hedge funds and other institutional investors own 65.60% of the company’s stock.
Bruker (NASDAQ:BRKR) last issued its earnings results on Thursday, November 2nd. The medical research company reported $0.29 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.27 by $0.02. The business had revenue of $435.60 million during the quarter, compared to analyst estimates of $415.45 million. Bruker had a return on equity of 25.83% and a net margin of 8.85%. Bruker’s revenue for the quarter was up 10.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.32 earnings per share. equities research analysts anticipate that Bruker will post 1.19 EPS for the current year.
The business also recently disclosed a quarterly dividend, which was paid on Friday, December 22nd. Shareholders of record on Monday, December 4th were given a $0.04 dividend. The ex-dividend date of this dividend was Friday, December 1st. This represents a $0.16 annualized dividend and a yield of 0.45%. Bruker’s payout ratio is currently 17.02%.
Bruker Company Profile
Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.
Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.